Trial Profile
Multi-institutional, Randomized, Double-Blind, Placebo-Control, Factorial Design, 4-arms, 8 Week Administration, Phase 3 Clinical Study for Patients With Hypertension Associated With Dyslipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Aug 2013
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil/rosuvastatin (Primary) ; Olmesartan medoxomil; Rosuvastatin
- Indications Dyslipidaemias; Hypertension
- Focus Registrational; Therapeutic Use
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jan 2013 New trial record